Valuation: Axonics, Inc.

Market Cap 3.63B 3.22B 3.01B 2.74B 5.17B 349B 5.22B 36.41B 14.11B 178B 13.62B 13.32B 572B P/E 2022
-48.9x
P/E 2023 -502x
Enterprise Value 3.31B 2.94B 2.75B 2.5B 4.72B 318B 4.76B 33.22B 12.87B 163B 12.43B 12.16B 522B EV / Sales 2022
10x
EV / Sales 2023 7.74x
Free-Float
99.8%
Yield 2022 *
-
Yield 2023 -
3 years 48.3
Extreme 48.3
71.05
5 years 38.41
Extreme 38.41
79.92
10 years 11.95
Extreme 11.95
79.92
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 2013-09-30
Director of Finance/CFO 41 2023-10-01
Chief Operating Officer 47 2018-07-31
Director TitleAgeSince
Director/Board Member 69 2018-01-31
Director/Board Member 74 2019-04-07
Date Insider Type Main position Quantity % Market Cap. Importance
11/15/24 Issuer sale

Executive/Senior Manager

59,355 0.1161%
11/15/24 Issuer sale

Responsable ventes & marketing

109,664 0.2145%
11/15/24 Issuer sale

Chief Technology Officer

63,237 0.1237%
Change 5-day change 1-year change 3-year change Capi.($)
+0.75%-.--%-.--%+28.40% 3.63B
+0.84%-3.74%-27.56%+1.79% 169B
-0.07%-2.55%-11.59%+12.86% 110B
+0.90%+1.13%-25.66%+3.60% 106B
-1.24%-0.76%-49.50%-12.08% 73.87B
-0.24%+0.69%+2.08%+71.44% 58.98B
-0.86%+2.96%+12.91%+61.58% 51.28B
-0.71%-3.82%-8.68%-31.71% 48.16B
+0.12%-0.17%-17.87%+21.91% 40.84B
-1.01%-1.45%+27.31%-6.14% 32.21B
Average -0.15%-0.77%-9.86%+15.16% 69.38B
Weighted average by Cap. +0.03%-1.29%-16.98%+11.32%

Financials

2022 2023
Net sales 274M 243M 227M 207M 390M 26.31B 394M 2.75B 1.06B 13.45B 1.03B 1.01B 43.17B 366M 326M 304M 277M 522M 35.22B 527M 3.68B 1.42B 18.01B 1.38B 1.35B 57.79B
Net income -59.7M -53.04M -49.51M -45.12M -85.1M -5.74B -85.89M -599M -232M -2.93B -224M -219M -9.42B -6.09M -5.41M -5.05M -4.6M -8.68M -585M -8.76M -61.1M -23.68M -299M -22.86M -22.36M -960M
Net Debt -348M -309M -289M -263M -496M -33.46B -501M -3.49B -1.35B -17.11B -1.31B -1.28B -54.9B -317M -282M -263M -240M -452M -30.51B -457M -3.18B -1.23B -15.6B -1.19B -1.17B -50.05B
Logo Axonics, Inc.
Axonics, Inc. is a medical technology company, which develops and commercializes products to treat adults with bladder and bowel dysfunction. The Company has designed and developed both rechargeable (R20) and recharge-free (F15) implantable sacral neuromodulation (SNM) systems, which deliver mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder (OAB), urinary retention (UR) and fecal incontinence (FI). The recharge-free implantable neurostimulator (INS) is approximately 10cc in volume, utilizes constant current stimulation, an easy-to-use, intuitive recharge-free patient remote control and other related accessories. It engineered its recharge-free sacral neuromodulation (SNM) system to deliver constant-current stimulation. Its SNM system includes an easy-to-use wireless patient remote control that does not require recharging or replacement batteries.
Employees
797
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. AXNX Stock